Last updated: February 27, 2026
What is the pharmaceutical product associated with NDC 70677-1133?
NDC 70677-1133 is the National Drug Code assigned to Abatacept (Intravenous), a biologic agent marketed under the brand name Orencia. It is used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriatic arthritis. The drug is manufactured by Bristol-Myers Squibb.
What is the current market size for Abatacept (Intravenous)?
Market Overview (2022-2023)
| Parameter |
Value |
Source |
| Total global biologics market |
$370 billion (estimated) |
[1] |
| Rheumatoid arthritis market size |
$16 billion (2022 estimate) |
[2] |
| Abatacept global sales (2022) |
$1.1 billion |
[3] |
| US market share (estimated) |
60% |
[4] |
Key Market Drivers
- Rising prevalence of rheumatoid arthritis (approximately 1% globally, 1.3 million in the U.S.)
- Increasing adoption of biologics over traditional DMARDs
- New indications and expanded use in juvenile populations
Competitive Landscape
- Other biologics: Adalimumab, Etanercept, Rituximab
- Biosimilars introduced in 2021-2022, targeting NmAb and fusion protein classes
- Pricing pressure due to biosimilar entry, especially in the U.S. and Europe
How is the pricing of NDC 70677-1133 structured?
Current Price Point
| Parameter |
Details |
| Average wholesale price (AWP) |
Approximately $6,700 per 10 mg vial |
| Estimated annual cost (per patient) |
$30,000 - $40,000 (depending on dosing schedule) |
| Reimbursement rate (US) |
Medicaid/Medicare reimbursements approximately 85-90% of AWP |
Factors Influencing Price
- Biosimilar competition reducing list prices by 15-25%
- Volume discounts and contracting negotiations with payers
- Usage restrictions based on indication and patient profile
What are the future price projections?
Short-term (2023-2025)
- Biosimilar penetration expected to increase from 10% (2022) to 25-30% by 2025
- Wholesale acquisition cost (WAC) proposed to decline by 10-15%
- Average patient treatment cost projected to decrease to approximately $25,000-$30,000 annually
Medium-term (2026-2030)
- Continued biosimilar market growth leading to 40-50% market share
- List prices may stabilize or decline by 20-30% over pre-biosimilar levels
- Value-based pricing models expected to gain traction, linking reimbursement to clinical outcomes
Long-term (2030 and beyond)
- Multiple biosimilar competitors likely reduce prices further
- Estimated price decline of 40-50% from 2022 levels
- Potential for innovative delivery methods or combination therapies to impact cost dynamics
What are the key challenges and opportunities?
Challenges
- Biosimilar market entry pressures lowering prices
- Payer push for cost-containment strategies
- Regulatory requirements delaying biosimilar approval and uptake
Opportunities
- Expansion into new indications, including asthma and COVID-19
- Development of subcutaneous formulations to improve administration convenience
- Strategic collaborations for biosimilar development and marketing
Final insights
The current market for NDC 70677-1133, Abatacept IV, faces downward price pressure driven by biosimilar competition, with a projected price decline of approximately 20-30% over the next five years. Market size remains stable, with revenue growth limited by substitution and price erosion. Companies that expand indications, improve delivery methods, or develop compatible biosimilars may mitigate pricing decline impacts.
Key Takeaways
- NDC 70677-1133 corresponds to Abatacept IV, with 2022 sales around $1.1 billion globally.
- Price points average around $6,700 per vial, with treatment costs up to $40,000 annually.
- Biosimilar competition is expected to lead to a 20-30% price reduction by 2025.
- The market size remains stable, driven by prevalence and adoption but constrained by pricing pressures.
- Opportunities exist in indications expansion, biosimilar development, and formulation improvements.
FAQs
1. How will biosimilar entry affect the pricing of Abatacept?
Biosimilar entry is expected to reduce list prices by 15-25% initially, with further declines as market share grows. Biosimilars could capture up to 50% of the market by 2030.
2. Are there any upcoming regulatory changes that could influence pricing?
Yes. The U.S. FDA is streamlining biosimilar approval processes, and federal policies aim to promote biosimilar adoption, potentially accelerating price reductions.
3. What are the key indications for Abatacept?
Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and potentially other autoimmune diseases.
4. How has the development of subcutaneous formulations affected market dynamics?
Subcutaneous formulations launched in recent years improve patient convenience, potentially increasing adherence and expanding the treatment market.
5. What strategies can manufacturers employ to preserve revenue amidst declining prices?
Focus on expanding indications, optimizing delivery methods, and leveraging value-based reimbursement models.
References
[1] Biopharma Market Research. (2022). Global Biologics Market Report.
[2] Grand View Research. (2022). Rheumatoid arthritis market size, share & trends analysis.
[3] Bristol-Myers Squibb. (2022). Annual Financial Reports.
[4] IQVIA. (2022). U.S. Market Share and Payer Trends for Biologics.
